COVID-19 Vaccines: The Status and Perspectives in Delivery Points of View

Overview

Journal Adv Drug Deliv Rev

Specialty Pharmacology

Date 2020 Dec 28

PMID 33359141

Citations 187

Authors

Jee Young Chung

Melissa N Thone

Young Jik Kwon

Affiliations

Soon will be listed here.

Abstract

Due to the high prevalence and long incubation periods often without symptoms, the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected millions of individuals globally, causing the coronavirus disease 2019 (COVID-19) pandemic. Even with the recent approval of the anti-viral drug, remdesivir, and Emergency Use Authorization of monoclonal antibodies against S protein, bamlanivimab and casirimab/imdevimab, efficient and safe COVID-19 vaccines are still desperately demanded not only to prevent its spread but also to restore social and economic activities via generating mass immunization. Recent Emergency Use Authorization of Pfizer and BioNTech's mRNA vaccine may provide a pathway forward, but monitoring of long-term immunity is still required, and diverse candidates are still under development. As the knowledge of SARS-CoV-2 pathogenesis and interactions with the immune system continues to evolve, a variety of drug candidates are under investigation and in clinical trials. Potential vaccines and therapeutics against COVID-19 include repurposed drugs, monoclonal antibodies, antiviral and antigenic proteins, peptides, and genetically engineered viruses. This paper reviews the virology and immunology of SARS-CoV-2, alternative therapies for COVID-19 to vaccination, principles and design considerations in COVID-19 vaccine development, and the promises and roles of vaccine carriers in addressing the unique immunopathological challenges presented by the disease.

Citing Articles

Influenza Neuraminidase Virus-Like Particle-Based Nanocarriers as a New Platform for the Delivery of Small-Peptide Antigens.

Khanefard N, Trianti I, Akeprathumchai S, Mekvichitsaeng P, Roshorm Y, Poomputsa K Mol Biotechnol. 2025; .

PMID: 40021575 DOI: 10.1007/s12033-025-01403-x.

Prevalence of Adverse Events Reported Following the First Dose of COVID-19 Vaccines in Bahia State, Brazil, from 2021 to 2022.

Saavedra R, Paixao E, Ichihara M, Costa M, Carvalho-Sauer R, de Castro C Vaccines (Basel). 2025; 13(2).

PMID: 40006708 PMC: 11861607. DOI: 10.3390/vaccines13020161.

The prevalence and influencing factors of COVID-19 in pregnant women post-relaxation of epidemic control measures in Hunan Province, China.

Wang Y, Liu Y, Zou K, Yang M, Wu Y, Xie D Front Med (Lausanne). 2025; 12:1485157.

PMID: 39963437 PMC: 11830578. DOI: 10.3389/fmed.2025.1485157.

Safety and Immunogenicity of the Live Attenuated Vaccine QazCOVID-Live Against Coronavirus Infection COVID-19: Pre-Clinical Study Results.

Kutumbetov L, Myrzakhmetova B, Tussipova A, Zhapparova G, Tlenchiyeva T, Bissenbayeva K Vaccines (Basel). 2025; 12(12.

PMID: 39772061 PMC: 11728456. DOI: 10.3390/vaccines12121401.

Antiseptics: An expeditious third force in the prevention and management of coronavirus diseases.

Okeke K, Ahamefule C, Nnabuife O, Orabueze I, Iroegbu C, Egbe K Curr Res Microb Sci. 2024; 7:100293.

PMID: 39497935 PMC: 11532748. DOI: 10.1016/j.crmicr.2024.100293.

References

Liu M . A Comparison of Plasmid DNA and mRNA as Vaccine Technologies. Vaccines (Basel). 2019; 7(2). PMC: 6631684. DOI: 10.3390/vaccines7020037. View

Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y . Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019. Clin Infect Dis. 2020; 71(16):2027-2034. PMC: 7184337. DOI: 10.1093/cid/ciaa344. View

Wu Z, McGoogan J . Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239-1242. DOI: 10.1001/jama.2020.2648. View

Lurie N, Saville M, Hatchett R, Halton J . Developing Covid-19 Vaccines at Pandemic Speed. N Engl J Med. 2020; 382(21):1969-1973. DOI: 10.1056/NEJMp2005630. View

Folegatti P, Bittaye M, Flaxman A, Lopez F, Bellamy D, Kupke A . Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet Infect Dis. 2020; 20(7):816-826. PMC: 7172901. DOI: 10.1016/S1473-3099(20)30160-2. View

Tian X, Li C, Huang A, Xia S, Lu S, Shi Z . Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. Emerg Microbes Infect. 2020; 9(1):382-385. PMC: 7048180. DOI: 10.1080/22221751.2020.1729069. View

Dutta N, Mazumdar K, Gordy J . The Nucleocapsid Protein of SARS-CoV-2: a Target for Vaccine Development. J Virol. 2020; 94(13). PMC: 7307180. DOI: 10.1128/JVI.00647-20. View

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

Chen J, Hu C, Chen L, Tang L, Zhu Y, Xu X . Clinical Study of Mesenchymal Stem Cell Treatment for Acute Respiratory Distress Syndrome Induced by Epidemic Influenza A (H7N9) Infection: A Hint for COVID-19 Treatment. Engineering (Beijing). 2020; 6(10):1153-1161. PMC: 7102606. DOI: 10.1016/j.eng.2020.02.006. View

10.

Yu H, Sun B, Fang Z, Zhao J, Liu X, Li Y . Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients. Eur Respir J. 2020; 56(2). PMC: 7236821. DOI: 10.1183/13993003.01526-2020. View

11.

Zhang Y, Kutateladze T . Molecular structure analyses suggest strategies to therapeutically target SARS-CoV-2. Nat Commun. 2020; 11(1):2920. PMC: 7286911. DOI: 10.1038/s41467-020-16779-4. View

12.

Di Pasquale A, Preiss S, Da Silva F, Garcon N . Vaccine Adjuvants: from 1920 to 2015 and Beyond. Vaccines (Basel). 2015; 3(2):320-43. PMC: 4494348. DOI: 10.3390/vaccines3020320. View

13.

Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

14.

Fries C, Curvino E, Chen J, Permar S, Fouda G, Collier J . Advances in nanomaterial vaccine strategies to address infectious diseases impacting global health. Nat Nanotechnol. 2020; 16(4):1-14. DOI: 10.1038/s41565-020-0739-9. View

15.

Tillett R, Sevinsky J, Hartley P, Kerwin H, Crawford N, Gorzalski A . Genomic evidence for reinfection with SARS-CoV-2: a case study. Lancet Infect Dis. 2020; 21(1):52-58. PMC: 7550103. DOI: 10.1016/S1473-3099(20)30764-7. View

16.

Barouch D, Tomaka F, Wegmann F, Stieh D, Alter G, Robb M . Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet. 2018; 392(10143):232-243. PMC: 6192527. DOI: 10.1016/S0140-6736(18)31364-3. View

17.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

18.

Jiang F, Deng L, Zhang L, Cai Y, Cheung C, Xia Z . Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19). J Gen Intern Med. 2020; 35(5):1545-1549. PMC: 7088708. DOI: 10.1007/s11606-020-05762-w. View

19.

Zhang L, Jackson C, Mou H, Ojha A, Peng H, Quinlan B . SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity. Nat Commun. 2020; 11(1):6013. PMC: 7693302. DOI: 10.1038/s41467-020-19808-4. View

20.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View